![]()
|
|
||||||||
J. Biol. Chem., Vol. 276, Issue 42, 38929-38933, October 19, 2001
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the
Received for publication, August 3, 2001
In this work we have investigated the molecular
basis of the neuronal damage induced by the prion peptide by searching
for a surface receptor whose activation could be the first step of a
cascade of events responsible for cell death. By using a human neuroblastoma cell line lacking all the neurotrophin receptors and
derived clones expressing the full-length or truncated forms of the low
affinity neurotrophin receptor (p75NTR), we have been
able to demonstrate that the neuronal death induced by the prion
protein fragment PrP-(106-126) is an active process mediated by a) the
binding of the peptide to the extracellular region of
p75NTR, b) the signaling function of the intracytoplasmic
region of the receptor, and c) the activation of caspase-8 and the
production of oxidant species.
The aetiological agent of the prion diseases, a set of sporadic,
genetic, and infectious neurodegenerative disorders affecting humans
and animals, has been proposed to be an aberrant isoform of the cell
surface glycoprotein
(PrPC)1 named
Scrapie prion protein (PrPSc), which arises
posttranslationally via conformational changes converting
PrPC into PrPSc (1, 2). So far, the mechanisms
by which the extracellular deposition of PrPSc, a protein
characterized by its high content of In recent years, it has been demonstrated that a prion protein
fragment, PrP-(106-126), could induce neuronal death by apoptosis in
rat hippocampal cultures (3). This peptide mimics the physico-chemical properties of PrPSc by exhibiting a prevalent In the search for a prion receptor we focused our attention on the p75
low affinity NGF receptor, which belongs to the family of death
receptors (13) and can trigger apoptosis (14-16). The rationale of
this investigation was 2-fold. First, it has been observed that
PrP-(106-126) exhibits a prevalent Materials--
The peptide PrP-(106-126), synthesized as
previously described (3), was a generous gift of Prof. S. Salvadori
(Department of Pharmaceutical Sciences, University of Ferrara, Italy)
or was purchased from Bachem (Budendorf).
125I-PrP-(106-126) was prepared by Amersham Pharmacia
Biotech. Scrambled PrP-(106-126) was a kind gift of Dr. M. Salmona
(Istituto Mario Negri, Milano). Peptides were dissolved in 200 mM phosphate buffer, pH 5.0, and aged for 2-3 days at
37 °C to increase fibrillogenesis, which was measured with the
Thioflavin test. Goat polyclonal antibody sc-6189 against a peptide
mapping at the amino terminus of human p75NTR was purchased
from Santa Cruz Biotechnology. All the chemicals, when not indicated,
were from Sigma.
p75NTR Constructs--
All p75NTR
constructs were generated via different strategies. The wild type
p75NTR construct was produced by cloning the
p75NTR cDNA into the pCEP4 Cell Clones and Detection of p75NTR mRNA and
Proteins--
The parental neuroblastoma SK-N-BE cells (20)
(BENTR-free) were grown in RPMI 1640 medium containing fetal
bovine serum (15% v/v) and antibiotics. The cells were transfected
with the different pCEP4 Cytotoxicity of PrP-(106-126)--
Cells were plated
(10,000/cm2) in RPMI medium supplemented with fetal bovine
serum (15% v/v), glutamine (2.0 mM), gentamycine (50 µg/ml) and hygromycin (150 µg/ml in the case of the transfected cells) and maintained at 37 °C in humidified atmosphere of air with
5% (v/v) CO2 added. Two days later, the growth medium was replaced with fresh RPMI medium containing fetal bovine serum (1% v/v)
and PrP-(106-126) or staurosporine. When required the inhibitors of
caspases Z-Val-Ala-DL-Asp-fluoromethyl-ketone (Z-VAD-FMK) or
Z-Ile-Glu-Thr-Asp-fluoromethyl-ketone (Z-IETD-FMK) (Calbiochem) or of
NADPH oxidase diphenyleneiodonium were added 2 h before prion
peptide or staurosporine. Specimens were sampled at various intervals
thereafter. The cell damage was assessed by means of epifluorescence
microscopy after staining the plated cells with a solution 1:1 (v/v) of
acridine orange (0.1 mg/ml in phosphate-buffered saline; filter setting
for fluorescein isothiocyanate) and ethidium bromide (0.1 mg/ml in
phosphate-buffered saline; filter setting for rhodamine) according to
Spector et al. (21).
Binding Assay--
Cells plated as for cytotoxic assays were
incubated with 0.4 nM 125I-PrP-(106-126) in
the presence or absence of 1000-fold excess of cold aggregated peptide
for 3 h at 4 °C. The cells were next rinsed with ice-cold
phosphate-buffered saline and lysed in 1.0 M NaOH, and the
lysates were subjected to We have studied the effects of PrP-(106-126) on both the human
neuroblastoma SK-N-BE cells (BENTR-free), which express
neither p75NTR nor any of the high affinity neurotrophin
receptors (Trks) (20), and SK-N-BE cell clones expressing the
full-length p75NTR (BEp75) (Fig.
1). The cell damage was analyzed by
double staining of the specimens with both the cell-permeable acridine
orange and the cell-impermeable ethidium bromide (21) as shown in Fig. 2. The results of these analyses,
summarized in Fig. 3, A
and B, demonstrate that PrP-(106-126) could induce cell
death in BEp75 cell clones, while being totally harmless for
BENTR-free parental cells and for SK-N-BE cells
transfected with an empty pCEP4 Two mechanisms could be responsible for the function of
p75NTR in the cell damage by the prion peptide. This
receptor might be merely permissive for the cytotoxic action of
PrP-(106-126) elicited via a mechanism independent of the actual
binding of the peptide as in the case of excitotoxicity (22).
Alternatively, the binding of prion peptide to p75NTR might
be directly involved in cell death. A series of experimental findings
shows that the latter mechanism is the most likely one.
First, we have treated SK-N-BE-derived cell clones expressing a
truncated p75NTR (BEp75
Neurotrophin p75 Receptor Is Involved in Neuronal
Damage by Prion Peptide-(106-126)*
,
§,
,
,
, and
Department of Pathology, Section of General
Pathology, University of Verona, Strada Le Grazie 8, Verona 37134, Italy, the ¶ Department of Biomedical and Surgical Sciences,
Section of Histology and Embryology, University of Verona, Strada Le
Grazie 8, Verona 37134, Italy, and the
Department of Biology,
University of Bologna, Via Selmi 3, Bologna 40126, Italy
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
-pleated sheet and ability to
form amyloid fibrils, elicits the neuropathological changes of the
prion diseases, i.e. spongiform degeneration, neuronal loss,
and appearance of reactive astrocytes and microglial cells (1), had
remained unknown.
-pleated
structure and forming amyloid fibrillar aggregates that are partially
resistant to proteolysis (4). The ability of PrP-(106-126) to elicit a
neurotoxic effect has been widely confirmed (5-8) and, hence, it is
considered a valid model for studies into the mechanisms of neuronal
damage by prions. So far, the knowledge of such mechanisms had remained rather limited despite a series of recent findings, the most
significant of which are: a) the binding of the prion peptide to
cellular prion protein PrPC and the consequent inhibition
of PrPC function (9); b) the perturbation of ion
(especially calcium) homeostasis (6, 10, 11); c) the induction of
oxidative stress (12); and d) the cooperative pathogenetic role of the activation of microglia with production of oxidant species (5).
-sheet structure and forms
fibrillar aggregates similarly to
-amyloid peptides (4). Second, the
-amyloid peptides of Alzheimer's disease may exert their neurotoxic
action via an interaction with p75NTR (17-19). The data
herein presented support the view that the prion peptide-mediated cell
damage occurs through its interaction with the p75 neurotrophin receptor.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
vector within the
PvuII site. The deletion mutants p75
ICD and
p75
ECD were obtained by polymerase chain reaction
utilizing specific primers that introduce either a deletion of the
carboxyl-terminal domain or specific internal deletions within the
extracellular cysteine-rich domains or the intracellular domains. The
scheme of full-length p75NTR and of the truncated forms of
the receptor is reported in Fig. 1A.
-p75NTR constructs using the
polyethylene-immine method. After transfection, the cells were split
and grown in RPMI medium containing hygromycin (150 µg/ml) to allow
for the selection of positive clones. Surviving clones were picked,
expanded, and characterized for expression of both wild type and
mutated p75NTR proteins. All clones were tested for
expression of mRNA by Northern blot analysis (Fig. 1C)
as previously described (20). Briefly, total RNA was extracted from
cell clones by Tri-Reagent (Sigma) following manufacturer protocol. 15 µg of total RNA have been loaded per lane and run on a 3%
formaldeyde,1.5% agarose gel, transferred to a nylon membrane (Hybond
N+, Amersham Pharmacia Biotech) and probed with the
p75NTR full-length cDNA labeled with 32P
using MegaPrime kit (Amersham Pharmacia Biotech) following the manufacturer protocol. For the Western blot analysis cell lysates were
processed as previously described (20), and the expression of
p75NTR protein was tested using 9992 rabbit polyclonal
antiserum (a gift from Dr. M. V. Chao), which recognizes the
intracellular region of the receptor (Fig. 1D). For each
p75NTR construct, a battery of cell clones expressing
comparable levels of either full-length or truncated proteins was
chosen for the experimental work. The correct localization of the
p75NTR proteins in the plasmamembrane was detected
immunohistochemically (Fig. 1B). Cells were permeabilized
with 0.1% Triton X-100 and then stained with the rabbit polyclonal
antiserum (9992), or a mouse monoclonal antibody (ME 20.4) (a gift from
Dr. M. V. Chao) raised against the p75NTR extracellular
region (20).
counting. For Scatchard analysis of the
aggregated PrP-(106-126) binding to p75NTR-expressing
cells 0.4 nM 125I-PrP-(106-126) was used as
tracer and increasing concentrations of aggregated cold peptide were
used as competitor. For competition analysis 0.4 nM
125I-PrP-(106-126) was used as tracer and increasing
concentrations of NGF and antibody sc-6189 were used. For each point of
the Scatchard analysis nonspecific binding, determined with a 1000-fold
excess of cold competitor, was subtracted from total binding.
![]()
RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
vector (not shown). Importantly, the
neurotoxic action of PrP-(106-126) on BEp75 cell clones was
detectable already at very low concentrations (Fig. 3C).
Scrambled PrP-(106-126) was unable to induce cell death in either cell
clones (not shown). To our knowledge, this is the first evidence that
p75NTR is involved in the neurotoxic activity of prion
peptide.

View larger version (44K):
[in a new window]
Fig. 1.
Expression of
p75NTR in cell clones. A,
schematic depiction of the full-length and truncated p75NTR
proteins expressed in transfected SK-N-BE neuroblastoma cells.
Specifically: p75, full-length receptor;
p75
ECD, lacking the extracellular region from amino acids
37-229; p75
ICD, lacking the entire cytoplasmic region
from amino acid 280. B, localization of the
p75NTR protein in the plasmamembrane by immunostaining with
9992 antiserum in BENTR-free, BEp75, and
BEp75
ECD cell clones and with monoclonal antibody ME20.4
in BEp75
ICD cell clone. The detection, performed by
Cy3-conjugated anti-rabbit IgG or anti-mouse IgG, shows the
localization of the respective p75NTR proteins in the
plasmamembrane. Nuclei were blue-stained with
4',6-diamidino-2-phenylindole. C, expression of
p75NTR mRNA (Northern blot) and D, protein
levels (Western blot) of p75NTR in BENTR-free
cell clone and in cell clones transfected with different constructs of
p75NTR.

View larger version (44K):
[in a new window]
Fig. 2.
Epifluorescence microscopic analysis
of cell damage by PrP-(106-126). A1 and A2,
BEp75 cells control and treated for 72 h with 20 µM PrP-(106-126), respectively. B1 and
B2, BENTR-free cells control and treated for
72 h with 20 µM PrP-(106-126), respectively. The
intense yellow fluorescence by acridine orange in the nuclei
(arrowheads) reveals the progressive chromatin condensation,
collapse, and marginalization proper of apoptosis. The pale
green fluorescence by acridine orange in the nuclei reveals
the normal cells. The bright red fluorescence by ethidium
bromide denotes nuclei of cells in which membrane integrity was lost as
the death process had shifted from apoptosis to necrosis
(arrows). +, mitosis.

View larger version (28K):
[in a new window]
Fig. 3.
Time-course and dose-response of the effect
of PrP-(106-126). Time-course of the effect of PrP-(106-126) (20 µM) on BEp75 cells (A) and on
BENTR-free cells (B). Data are
reported as means ± S.D. of six experiments. C,
dose-response effect of PrP-(106-126) on BEp75 and
BENTR-free cells. Data are reported as means ± S.D. of
three experiments.
ECD) (Fig. 1) lacking
the four cysteine-rich repeats of the extracellular region either with
PrP-(106-126) or with staurosporine. The results (Fig.
4) show that, while being still
susceptible to staurosporine-elicited apoptosis,
BEp75
ECD cells were insensitive to the cytotoxic effects
of PrP-(106-126), a finding indicating the requirement of the
extracellular region of p75NTR for the cytotoxic effect of
PrP-(106-126).

View larger version (21K):
[in a new window]
Fig. 4.
Cell damage by PrP-(106-126) and by
staurosporine in different cell clones. Data are reported as
means ± S.D. of six experiments with BEp75 cells and
of at least four experiments with the other clones. PrP-(106-126), 20 µM; staurosporine, 50 nM.
Second, we have shown that PrP-(106-126) binds to p75NTR.
In fact, the results reported in Fig.
5A show that
125I-PrP-(106-126) binds to BEp75 cells but
not to BENTR-free cells or to BEp75
ECD
cells lacking the extracellular region of the receptor. The specificity
of the binding was shown by its competitive inhibition by an excess of
cold aggregated PrP-(106-126). Scatchard analysis (Fig. 5C)
showed that the binding of the aggregated peptide to p75NTR
occurs with a kd of 4.6 ± 0.7 nM (n = 4) and is saturable (Fig. 5B). The specificity of the binding was also shown by the
finding that it was inhibited by the antibody sc-6189 raised against
the amino terminus of p75NTR (Fig. 5D) and by
NGF (Fig. 5E). Since NGF binds to p75NTR with a
kd of 4-7 nM (18), which is similar
to that of PrP-(106-126), the high concentration of NGF required for
inhibiting the binding of the prion peptide may indicate that the two
ligands interact with different sites of p75NTR.
|
The results so far presented, showing that PrP-(106-126) is cytotoxic
by binding to p75NTR, raise the problem of the role of this
receptor in cell death induced by the peptide. Two mechanisms could be
hypothesized. The binding of the prion peptide to p75NTR
might be able to activate the receptor and trigger the signals for cell
death via the receptor's intracellular region or it could serve solely
as an anchorage allowing for PrP-(106-126)-induced cell damage via
other mechanisms. We demonstrated the validity of the first hypothesis
by investigating the effect of PrP-(106-126) on cell clones expressing
a truncated p75NTR devoid of the entire intracellular
region (BEp75
ICD) (Fig. 1). The results reported in Fig.
4 show that these cells, despite normally binding the peptide (Fig.
5A), were insensitive to its toxic effect indicating that
the intracellular region of the receptor is necessary for signaling
cell death.
We have also investigated some of the biochemical events usually
involved in active cell death. The results (Fig.
6) demonstrate that
p75NTR-mediated cell death induced by PrP-(106-126) is
associated with the activation of caspases as it was fully suppressed
by either Z-VAD-FMK (100 µM), a nonspecific inhibitor of
caspases, or Z-IETD-FMK (20 µM), an inhibitor of
receptor-activable caspase-8. These findings are consistent with the
concept that prion peptide-elicited neuronal cell death via
p75NTR is an active process that, by involving caspase-8,
is reminiscent of the cell death induced by other members of the death
receptors family (13). The data of Fig. 6 show that the cytotoxic
effect of 50 nM staurosporine, a receptor-independent
apoptogenic drug, was sensitive to Z-VAD-FMK but could not be
suppressed by Z-IETD-FMK. The results of Fig. 6 also show that
diphenyleneiodonium (100 nM), an inhibitor of NADPH
oxidase, the enzyme forming reactive oxygen intermediates, and other
flavo-protein dehydrogenases (23), could fully suppress the cell death
by PrP-(106-126) mediated by p75NTR. This finding agrees
with the notion that an oxidative stress is involved in the
pathogenesis of cell damage by prion peptide (12).
|
Our results, showing that PrP-(106-126) damages neuronal cells by activating p75NTR, raise a series of problems to be investigated. These problems include the types of interaction such as the type of interaction of the prion peptide with the extracellular region of p75NTR, the signaling function of the different domains of the intracellular region, the identification of the events occurring down-stream the intracellular region (24, 25), and the comparison of the role of p75NTR with that of other cell surface proteins recently found to interact with prion peptide as the receptor for advanced glycation end-products (RAGE) (26), a 66-kDa protein with unknown function (27, 28), a 37-kDa laminin receptor precursor (29), the formyl peptide receptor-like 1 (30), and the PrPC itself (9).
The therapeutic and/or preventive strategies concerning the prion
diseases are related to the mechanisms of formation and propagation of
PrPSc and to the pathogenesis of the neuronal damage by
PrPSc. It is likely that the results presented herein
obtained by using the model of PrP-(106-126)-neurotoxic effect open
new avenues for effective therapeutic strategies. Further studies will
clarify if the neurotoxicity of purified infective PrPSc
protein involves mechanisms similar to those of the PrP-(106-126) peptide.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Prof. S. Salvadori for the synthesis of PrP-(106-126) and Dr. M. Salmona (Istituto di Ricerche Farmacologiche Mario Negri (Milano, Italy) for the synthesis of scrambled PrP-(106-126).
| |
FOOTNOTES |
|---|
* This work was supported by grants from Progetto Sanità 1996-97, Fondazione Cariverona (to F. R. and U. A.), Cofinanziamento Ministero dell'Università e della Ricerca Scientifica e Tecnologica-Università (to F. R. and U. A.), and from 5th Framework Program of the European Union Grant NOQLRT-1999-00573 (to G. D. V.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ To whom correspondence should be addressed. Tel.: 39-045-8027121; Fax: 39-045-8027127; E-mail: Filippo.Rossi@univr.it.
Published, JBC Papers in Press, August 6, 2001, DOI 10.1074/jbc.M107454200
| |
ABBREVIATIONS |
|---|
The abbreviations used are: PrP, prion protein fragment; NGF, nerve growth factor; Z-VAD-FMK, benzyloxycarbonyl-Val-Ala-DL- Asp-fluoromethylketone; Z-IETD-FMK, benzyloxycarbonyl-Ile-Glu-Thr-Asp-fluoromethylketone; DPI, diphenyleneiodonium.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Prusiner, S. B. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 13636-13383 |
| 2. | Aguzzi, A., and Weissmann, C. (1997) Nature 389, 795-798[CrossRef][Medline] [Order article via Infotrieve] |
| 3. | Forloni, G., Angeretti, N., Chiesa, R., Monzani, E., Salmona, M., Bugiani, O., and Tagliavini, F. (1993) Nature 362, 543-546[CrossRef][Medline] [Order article via Infotrieve] |
| 4. | Selvaggini, C., De Gioia, L., Cantù, L., Ghibaudi, E., Diomede, L., Passerini, F., Forloni, G., Bugiani, O., Tagliavini, F., and Salmona, M. (1993) Biochem. Biophys. Res. Commun. 194, 1380-1386[CrossRef][Medline] [Order article via Infotrieve] |
| 5. | Brown, D. R., Schmidt, B., and Kretzschmar, H. A. (1996) Nature 380, 345-347[CrossRef][Medline] [Order article via Infotrieve] |
| 6. | Florio, T., Thellung, S., Amico, C., Robello, M., Salmona, M., Bugiani, O., Tagliavini, F., Forloni, G., and Schettini, G. (1998) J. Neurosci. Res. 54, 341-352[CrossRef][Medline] [Order article via Infotrieve] |
| 7. | Rymer, D. L., and Good, T. A. (2000) J. Neurochem. 75, 2536-2545[CrossRef][Medline] [Order article via Infotrieve] |
| 8. |
Ettaiche, M.,
Pichot, R.,
Vincent, J. P.,
and Chabry, J.
(2000)
J. Biol. Chem.
275,
36487-36490 |
| 9. | Brown, D. R. (2000) Biochem. J. 352, 511-518 |
| 10. |
Lin, M. C.,
Mirzabekov, T.,
and Kagan, B. L.
(1997)
J. Biol. Chem.
272,
44-47 |
| 11. |
Kristensson, K.,
Feuerstein, B.,
Taraboulos, A.,
Hyun, W. C.,
Prusiner, S. B.,
and DeArmond, S. J.
(1993)
Neurology
43,
2335-2341 |
| 12. | Guentchev, M., Voigtlander, T., Haberler, C., Groschup, M. H., and Budka, H. (2000) Neurobiol. Dis. 7, 270-273[CrossRef][Medline] [Order article via Infotrieve] |
| 13. | Nagata, S. (1997) Cell 88, 355-365[CrossRef][Medline] [Order article via Infotrieve] |
| 14. | Frade, J. M., Rodriguez-Tebar, A., and Barde, A-Y. (1996) Nature 383, 166-168[CrossRef][Medline] [Order article via Infotrieve] |
| 15. | Bredesen, D. E., and Rabizadeh, S. (1997) Trends Neurosci. 20, 287-290[CrossRef][Medline] [Order article via Infotrieve] |
| 16. | Coulson, E. J., Reid, K., and Bartlett, P. F. (1999) Mol. Neurobiol. 20, 29-44[Medline] [Order article via Infotrieve] |
| 17. |
Rabizadeh, S.,
Bittler, C. M.,
Butcher, L. L.,
and Bredesen, D. E.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
10703-10706 |
| 18. | Yaar, M., Zhai, S., Pilch, P. F., Doyle, S. M., Eisenhauer, P. B., Fine, R. E., and Gilchrest, B. A. (1997) J. Clin. Invest. 100, 2333-2340[Medline] [Order article via Infotrieve] |
| 19. | Kuner, P., Schubenel, R., and Hertel, C. (1998) J. Neurosci. Res. 54, 798-804[CrossRef][Medline] [Order article via Infotrieve] |
| 20. | Bunone, G., Mariotti, A., Compagni, A., Morandi, E., and Della Valle, G. (1997) Oncogene 14, 1463-1470[CrossRef][Medline] [Order article via Infotrieve] |
| 21. | Spector, D. L., Goldman, R. D., and Leinwald, L. A. (1998) Cells, A Laboratory Manual , Vol. 1 , pp. 15.6-15.7, Cold Spring Harbor Laboratory Press |
| 22. | Oh, J. D., Chartisathian, K., Chase, T. N., and Butcher, L. L. (2000) Brain Res. 853, 174-185[CrossRef][Medline] [Order article via Infotrieve] |
| 23. | O'Donnell, B. V., Tew, D. G., Jones, O. T., and England, P. J. (1993) Biochem. J. 290, 41-49 |
| 24. | Kaplan, D. R., and Miller, F. D. (2000) Curr. Opin. Neurobiol. 10, 381-391[CrossRef][Medline] [Order article via Infotrieve] |
| 25. | Meldolesi, J., Sciorati, C., and Clementi, E. (2000) Trends Pharmacol. Sci. 21, 242-243[CrossRef][Medline] [Order article via Infotrieve] |
| 26. | Yan, S. D., Zhu, H., Zhu, A., Golabek, A., Du, H., Roher, A., Yu, J., Soto, C., Schmidt, A. M., Stern, D., and Kindy, M. (2000) Nat. Med. 6, 643-651[CrossRef][Medline] [Order article via Infotrieve] |
| 27. | Martins, V. R., Graner, E., Garcia-Abreu, J., Souza, S. J., Mercadante, A. F., Veiga, S. S., Zanata, S. M., Neto, V. M., and Brentani, R. R. (1997) Nat. Med. 3, 1376-1382[CrossRef][Medline] [Order article via Infotrieve] |
| 28. | Martins, V. R., Mercadante, A. F., Cabral, A. L. B., Freitas, A. R. O., and Castro, R. M. R. P. S. (2001) Braz. J. Med. Biol. Res. 34, 585-595[Medline] [Order article via Infotrieve] |
| 29. | Rieger, R., Edenhofer, F., Lasmézas, C. I., and Weiss, S. (1997) Nat. Med. 3, 1383-1388[CrossRef][Medline] [Order article via Infotrieve] |
| 30. |
Le, Y.,
Yazawa, H.,
Gong, W., Yu, Z.,
Ferrans, V. J.,
Murphy, P. M.,
and Wang, J. M.
(2001)
J. Immunol.
166,
1448-1451 |
This article has been cited by other articles:
![]() |
C. Tuffereau, K. Schmidt, C. Langevin, F. Lafay, G. Dechant, and M. Koltzenburg The Rabies Virus Glycoprotein Receptor p75NTR Is Not Essential for Rabies Virus Infection J. Virol., December 15, 2007; 81(24): 13622 - 13630. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. R. Taylor, D. J. Gifondorwa, J. M. Newbern, M. B. Robinson, J. L. Strupe, D. Prevette, R. W. Oppenheim, and C. E. Milligan Astrocyte and Muscle-Derived Secreted Factors Differentially Regulate Motoneuron Survival J. Neurosci., January 17, 2007; 27(3): 634 - 644. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Pietri, A. Caprini, S. Mouillet-Richard, E. Pradines, M. Ermonval, J. Grassi, O. Kellermann, and B. Schneider Overstimulation of PrPC Signaling Pathways by Prion Peptide 106-126 Causes Oxidative Injury of Bioaminergic Neuronal Cells J. Biol. Chem., September 22, 2006; 281(38): 28470 - 28479. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Florez-McClure, D. A. Linseman, C. T. Chu, P. A. Barker, R. J. Bouchard, S. S. Le, T. A. Laessig, and K. A. Heidenreich The p75 Neurotrophin Receptor Can Induce Autophagy and Death of Cerebellar Purkinje Neurons J. Neurosci., May 12, 2004; 24(19): 4498 - 4509. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Bate, M. Salmona, L. Diomede, and A. Williams Squalestatin Cures Prion-infected Neurons and Protects Against Prion Neurotoxicity J. Biol. Chem., April 9, 2004; 279(15): 14983 - 14990. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. V. Chao Dependence Receptors: What Is the Mechanism? Sci. Signal., September 16, 2003; 2003(200): pe38 - pe38. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. C. Bronfman, M. Tcherpakov, T. M. Jovin, and M. Fainzilber Ligand-Induced Internalization of the p75 Neurotrophin Receptor: A Slow Route to the Signaling Endosome J. Neurosci., April 15, 2003; 23(8): 3209 - 3220. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. B. Jacoby Airway Neural Plasticity: The Nerves They Are A-Changin' Am. J. Respir. Cell Mol. Biol., February 1, 2003; 28(2): 138 - 141. [Full Text] [PDF] |
||||
![]() |
C. Langevin, H. Jaaro, S. Bressanelli, M. Fainzilber, and C. Tuffereau Rabies Virus Glycoprotein (RVG) Is a Trimeric Ligand for the N-terminal Cysteine-rich Domain of the Mammalian p75 Neurotrophin Receptor J. Biol. Chem., September 27, 2002; 277(40): 37655 - 37662. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. B. Brann, M. Tcherpakov, I. M. Williams, A. H. Futerman, and M. Fainzilber Nerve Growth Factor-induced p75-mediated Death of Cultured Hippocampal Neurons Is Age-dependent and Transduced through Ceramide Generated by Neutral Sphingomyelinase J. Biol. Chem., March 15, 2002; 277(12): 9812 - 9818. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |